Renal cancer drug market was valued at $7.05 billion in 2025 and is projected to reach $13.61 billion by 2035, growing at a CAGR of 6.8% during the forecast period (2026–2035). The rising prevalence of kidney cancer and increasing demand for targeted oncology therapies are significantly driving market growth. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2022, with kidney cancer representing a growing share of urological malignancies. The increasing incidence of renal cell carcinoma, particularly among aging populations, is strengthening demand for advanced drug therapies including immunotherapy and targeted therapy. The market is witnessing a strong shift toward precision medicine and biologic therapies. Regulatory approvals and clinical advancements are accelerating the adoption of immune checkpoint inhibitors and combination therapies. The U.S. Food and Drug Administration continues to approve novel oncology drugs targeting renal cancer, supporting improved treatment outcomes.

Rotary pump market was valued at $8.35 billion in 2025 and is projected to reach $13.40 billion by 2035, growing at a CAGR of 4.84% during the forecast period (2026–2035). The rising global demand for efficient fluid handling systems across industrial applications is a key macro driver supporting market growth. According to International Energy Agency, global oil demand reached approximately 102 million barrels per day in 2023, reflecting strong upstream and downstream activity. Rotary pumps play a critical role in transferring viscous fluids such as crude oil, chemicals, and wastewater with high efficiency and minimal pulsation. Increasing investments in energy, chemical processing, and water infrastructure are strengthening the adoption of advanced rotary pumping solutions across industries. Industrial expansion across oil & gas, chemical & petrochemical, and water & wastewater sectors continues to support steady demand for rotary pumps. According to UN Comtrade Database, global trade in chemical products exceeded $5 trillion in 2023, highlighting the scale of fluid handling requirements across production and distribution processes. 

Scopolamine market was valued at $209.8 million in 2025 and is projected to reach $439.4 million by 2035, growing at a CAGR of 4.3% during the forecast period (2026–2035). The rising prevalence of motion sickness, postoperative nausea and vomiting (PONV), and gastrointestinal disorders is significantly driving demand for scopolamine-based therapeutics across global healthcare systems. Increasing surgical procedures and expanding travel activities are further contributing to the growth of antiemetic drug demand worldwide. According to the World Health Organization, approximately 234 million major surgical procedures are performed annually worldwide, highlighting the growing need for effective PONV management solutions. Scopolamine, particularly in transdermal patch form, plays a critical role in reducing postoperative nausea, improving patient recovery outcomes, and enhancing healthcare efficiency.

Spina bifida treatment market was valued at $1.88 billion in 2025 and is projected to reach $3.25 billion by 2035, growing at a CAGR of 5.62% during the forecast period (2026–2035). The increasing prevalence of neural tube defects and rising awareness regarding early diagnosis and treatment are significantly driving market growth. Spina bifida, a congenital birth defect affecting the spinal cord, requires lifelong medical care, including surgical interventions, pharmacological treatments, and rehabilitation support. Advancements in fetal surgery techniques and growing adoption of minimally invasive procedures are further supporting treatment outcomes and expanding the market landscape. The integration of robotics and neurostimulation technologies into rehabilitation is also improving patient mobility and quality of life, thereby strengthening demand for advanced therapeutic solutions globally.

Vetronics market was valued at $5.22 billion in 2025 and is projected to reach $6.51 billion by 2035, growing at a CAGR of 4.54% during the forecast period (2026–2035). The increasing modernization of military vehicle fleets and rising global defense expenditure are strengthening demand for advanced vetronics systems across defense platforms. Governments worldwide are investing heavily in upgrading armored vehicles with advanced electronic systems such as command & control, surveillance, and communication technologies to enhance battlefield situational awareness and operational efficiency. Vetronics systems play a critical role in enabling real-time data processing, secure communication, and integrated battlefield management, essential for modern warfare environments. The market is witnessing steady adoption of AI-enabled vetronics and software-defined architectures as defense forces transition toward network-centric operations. 

Protein hydrolysate market was valued at $3.90 billion in 2025 and is projected to reach $6.25 billion by 2035, growing at a CAGR of 5.3% during the forecast period (2026–2035). The increasing global demand for high-quality protein ingredients driven by rising nutritional awareness is a key macro driver supporting market growth. According to the Food and Agriculture Organization (FAO), global protein consumption is steadily increasing due to population growth and changing dietary patterns, particularly in developing economies. Protein hydrolysates play a critical role in improving protein digestibility and bioavailability, making them highly suitable for applications such as infant nutrition, clinical nutrition, and sports supplements.

Protein expression market was valued at $3.05 billion in 2025 and is projected to reach $6.21 billion by 2035, growing at a CAGR of 7.37% during the forecast period (2026–2035). The rising demand for biologics and recombinant proteins is significantly driving the adoption of advanced protein expression technologies across pharmaceutical and biotechnology industries. Protein expression systems are essential for producing therapeutic proteins, enzymes, and vaccines at scale, making them a critical component of modern drug development and life sciences research. The increasing burden of chronic diseases and the shift toward biologics-based therapies are accelerating market growth.

Polycarbonate resins market was valued at $17.00 billion in 2025 and is projected to reach $27.18 billion by 2035, growing at a CAGR of 4.8% during the forecast period (2026–2035). The rising global demand for lightweight and high-performance materials across the automotive and electronics industries is a key macro driver supporting market growth. According to the International Organisation of Motor Vehicle Manufacturers (OICA), global vehicle production reached approximately 93 million units in 2023, reflecting strong growth in automotive manufacturing. Polycarbonate resins play a critical role in reducing vehicle weight, improving fuel efficiency, and enhancing impact resistance in components such as lighting systems, interior trims, and electric vehicle battery housings. Increasing electrification of vehicles and stringent emission regulations are further accelerating the adoption of advanced engineering plastics such as polycarbonate across automotive applications.

Pediatric vaccine market was valued at $31.80 billion in 2025 and is projected to reach $62.50 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026–2035). The increasing expansion of national immunization programs and rising awareness of preventive healthcare are significantly driving demand for pediatric vaccines across global healthcare systems. Governments and global health agencies are prioritizing childhood immunization to reduce disease burden and mortality, thereby strengthening long-term demand for vaccines. The rising global immunization coverage is a major macro driver supporting market growth. According to the World Health Organization (WHO), routine immunization programs currently reach over 110 million infants annually, with global DTP3 vaccine coverage estimated at approximately 84%. WHO also states that immunization prevents between 3.5 million and 5 million deaths each year from vaccine-preventable diseases such as measles, tetanus, and diphtheria. 

Opioid use disorder treatment market was valued at $4.65 billion in 2025 and is projected to reach $12.82 billion by 2035, growing at a CAGR of 10.66% during the forecast period (2026–2035). The rising global burden of opioid dependence is a key macro driver supporting market growth. According to the World Health Organization (WHO), approximately 39.5 million people worldwide were suffering from drug use disorders, with opioids accounting for a significant share of drug-related deaths globally. The increasing prevalence of opioid misuse across both developed and developing economies is accelerating the demand for effective treatment solutions including pharmacotherapy and behavioural therapy interventions. Governments and healthcare organizations are strengthening addiction treatment programs, improving access to medications such as methadone, buprenorphine, and naltrexone, and expanding rehabilitation infrastructure, thereby supporting sustained market expansion.